Metastatic Uveal Melanoma: Treatment Strategies and Survival-Results from the Dutch Melanoma Treatment Registry.
Anouk JochemsMonique K Van der KooijMarta FioccoMaartje G SchouwenburgMaureen J AartsAlexander C van AkkooiFranchette W P J van den BerkmortelChristian U BlankAlfonsus J M van den EertweghMargreet G FrankenJanWillem B de GrootJohn B A G HaanenGeke A P HospersRutger H T KoornstraWim H J KruitMarieke LouwmanDjura PiersmaRozemarijn S van RijnKarijn P M SuijkerbuijkAlbert J Ten TijeGerard VreugdenhilMichel W J M WoutersMichiel C T van ZeijlKoos J M van der HoevenEllen H W KapiteijnPublished in: Cancers (2019)
Uveal melanoma (UM) is the most common primary intraocular tumor in adults. Up to 50% of UM patients will develop metastases. We present data of 175 metastatic UM patients diagnosed in the Netherlands between July 2012 and March 2018. In our cohort, elevated lactate dehydrogenase level (LDH) is an important factor associated with poorer survival (Hazard Ratio (HR) 9.0, 95% Confidence Interval (CI) 5.63-14.35), and the presence of liver metastases is negatively associated with survival (HR 2.09, 95%CI 1.07-4.08). We used data from the nation-wide Dutch Melanoma Treatment Registry (DMTR) providing a complete overview of the location of metastases at time of stage IV disease. In 154 (88%) patients, the liver was affected, and only 3 patients were reported to have brain metastases. In 63 (36%) patients, mutation analysis was performed, showing a GNA11 mutation in 28.6% and a GNAQ mutation in 49.2% of the analyzed patients. In the absence of standard care of treatment options, metastatic UM patients are often directed to clinical trials. Patients participating in clinical trials are often subject to selection and usually do not represent the entire metastatic UM population. By using our nation-wide cohort, we are able to describe real-life treatment choices made in metastatic UM patients and 1-year survival rates in selected groups of patients.